e-therapeutics plc (LON:ETX – Get Free Report) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 11.77 ($0.15) and traded as low as GBX 9.25 ($0.12). e-therapeutics shares last traded at GBX 9.40 ($0.12), with a volume of 4,821,033 shares traded.
e-therapeutics Stock Performance
The stock has a 50 day simple moving average of GBX 11.46 and a 200 day simple moving average of GBX 11.77. The company has a market cap of £54.93 million, a price-to-earnings ratio of -470.00 and a beta of 0.48. The company has a quick ratio of 20.13, a current ratio of 22.20 and a debt-to-equity ratio of 0.33.
About e-therapeutics
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet.
Further Reading
- Five stocks we like better than e-therapeutics
- Consumer Staples Stocks, Explained
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- What is a Dividend King?
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- How to Most Effectively Use the MarketBeat Earnings Screener
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for e-therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for e-therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.